•Oral immune-related adverse events in patients with and without inflammatory bowel disease receiving immune checkpoint inhibitor therapy
•A cross-sectional study on pharmacotherapy and predictors of clinical remission in patients with inflammatory bowel disease
•Design and Evaluation of Colon-Specific Epinastine Prodrugs as Potent Anti-Colitis Agents Acting via the Activation of the Nrf2-HO-1 Pathway
•Shorter infliximab infusion times without premedication do not increase adverse reactions
•Pancolitis due to Tuberculosis Masquerading as Inflammatory Bowel Disease in a 43-Year-Old Woman: Diagnostic Challenges in a Resource-Limited Setting-A Case Study and Literature Review From Ethiopia
